FIBROGEN INC (KYNB) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does FIBROGEN INC Do?
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. FIBROGEN INC (KYNB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Enrique A. Conterno and employs approximately 570 people, headquartered in San Francisco, California. With a market capitalization of $29M, KYNB is one of the notable companies in the Healthcare sector.
FIBROGEN INC (KYNB) Stock Rating — Reduce (April 2026)
As of April 2026, FIBROGEN INC receives a Reduce rating with a composite score of 35.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.KYNB ranks #2,627 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, FIBROGEN INC ranks #348 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
KYNB Stock Price and 52-Week Range
FIBROGEN INC (KYNB) currently trades at $7.17. The stock lost $0.02 (0.3%) in the most recent trading session. The 52-week high for KYNB is $12.60, which means the stock is currently trading -43.1% from its annual peak. The 52-week low is $0.23, putting the stock 3014.7% above its annual trough. Recent trading volume was 4K shares, suggesting relatively thin trading activity.
Is KYNB Overvalued or Undervalued? — Valuation Analysis
FIBROGEN INC (KYNB) carries a value factor score of 36/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.16x, compared to the Healthcare sector average of 23.63x — a discount of 99%. The price-to-book ratio stands at 2.83x, versus the sector average of 2.75x. The price-to-sales ratio is 5.30x, compared to 1.66x for the average Healthcare stock.
At current multiples, FIBROGEN INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
FIBROGEN INC Profitability — ROE, Margins, and Quality Score
FIBROGEN INC (KYNB) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -234.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 131.8% versus the sector average of -33.1%.
On a margin basis, FIBROGEN INC reports gross margins of 112.7%, compared to 71.5% for the sector. The operating margin is -10178.9% (sector: -66.1%). Net profit margin stands at 1090.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 7.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
KYNB Debt, Balance Sheet, and Financial Health
FIBROGEN INC has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $118M.
KYNB has a beta of -4.08, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for FIBROGEN INC is 41/100, reflecting average volatility within the normal range for its sector.
FIBROGEN INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, FIBROGEN INC reported revenue of $5M and earnings per share (EPS) of $49.61. Net income for the quarter was $181M. Gross margin was 112.7%. Operating income came in at $-80M.
In Q3 2025, FIBROGEN INC reported revenue of $1M and earnings per share (EPS) of $49.61. Net income for the quarter was $201M. Gross margin was 105.4%. Revenue grew 774.8% year-over-year compared to Q3 2024. Operating income came in at $-5M.
In Q2 2025, FIBROGEN INC reported revenue of $1M and earnings per share (EPS) of $-1.88. Net income for the quarter was $-8M. Gross margin was 93.7%. Revenue grew 35.1% year-over-year compared to Q2 2024. Operating income came in at $-12M.
In Q1 2025, FIBROGEN INC reported revenue of $3M and earnings per share (EPS) of $0.05. Net income for the quarter was $5M. Gross margin was 90.8%. Revenue grew -89.2% year-over-year compared to Q1 2024. Operating income came in at $-15M.
Over the past 8 quarters, FIBROGEN INC has experienced revenue contraction from $25M to $5M. Investors analyzing KYNB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
KYNB Dividend Yield and Income Analysis
FIBROGEN INC (KYNB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
KYNB Momentum and Technical Analysis Profile
FIBROGEN INC (KYNB) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.
KYNB vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, FIBROGEN INC (KYNB) ranks #348 out of 838 stocks based on the Blank Capital composite score. This places KYNB in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing KYNB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KYNB vs S&P 500 (SPY) comparison to assess how FIBROGEN INC stacks up against the broader market across all factor dimensions.
KYNB Next Earnings Date
No upcoming earnings date has been announced for FIBROGEN INC (KYNB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy KYNB? — Investment Thesis Summary
The quantitative profile for FIBROGEN INC suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 36/100 indicates premium valuation.
In summary, FIBROGEN INC (KYNB) earns a Reduce rating with a composite score of 35.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KYNB stock.
Related Resources for KYNB Investors
Explore more research and tools: KYNB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KYNB head-to-head with peers: KYNB vs AZN, KYNB vs SLGL, KYNB vs VMD.